Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma

Histopathology

Volumn 59, Issue 5, 2011, Pages 822-831

  Kim, Min A ^a   Lee, Hyuk Joon ^a   Yang, Han Kwang ^a   Bang, Yung Jue ^a   Kim, Woo Ho ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Fluorescence in situ hybridization; HER2; Immunohistochemistry; Stomach neoplasm; Tissue array analysis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ABDOMINAL WALL; ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER LOCALIZATION; COMPARATIVE STUDY; DIAPHRAGM; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MESENTERY; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECTUM; STOMACH CARCINOMA; UTERUS;

ADENOCARCINOMA; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 81555209828     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04012.x     Document Type: Article

References (25)

1. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986; 232; 1644-1646.
2. Xu YH, Richert N, Ito S, Merlino GT, Pastan I. Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines. Proc. Natl Acad. Sci. USA 1984; 81; 7308-7312.
3. Ross JS, Fletcher DA. ERBB2/neu (c-erb-B2) gene and protein in breast cancer. Am. J. Clin. Pathol. 1999; 112; S53-S67.
4. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001; 344; 783-792.
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 2005; 353; 1659-1672.
6. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005; 353; 1673-1684.
7. Nakajima M, Sawada H, Yamada Y et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999; 85; 1894-1902.
8. Kim MA, Jung EJ, Lee HS et al. Evaluation of ERBB2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum. Pathol. 2007; 38; 1386-1393.
9. Yano T, Doi T, Ohtsu A et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol. Rep. 2006; 15; 65-71.
10. Kimura M, Tsuda H, Morita D et al. A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma based on correlation of fluorescence in situ hybridization and immunohistochemical measurements. Virchows Arch. 2004; 445; 255-262.
11. Tanner M, Hollmen M, Junttila TT et al. Amplification of ERBB2 in gastric carcinoma: association with topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. 2005; 16; 273-278.
12. Van Cutsem E, Kang Y, Chung H et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer. J. Clin. Oncol. 2009; 27; 18S (Abstract).
13. Santinelli A, Pisa E, Stramazzotti D, Fabris G. ERBB2 status discrepancy between primary breast cancer and metastatic sites. Impacts on target therapy. Int. J. Cancer 2008; 122; 999-1004.
14. Vincent-Salomon A, Jouve M, Genin P et al. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer 2002; 94; 2169-2173.
15. Simon R, Nocito A, Hubscher T et al. Patterns of ERBB2/neu amplification and overexpression in primary and metastatic breast cancer. J. Natl Cancer Inst. 2001; 93; 1141-1146.
16. Gong Y, Booser DJ, Sneige N. Comparison of ERBB2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 2005; 103; 1763-1769.
17. Gancberg D, Di Leo A, Cardoso F et al. Comparison of ERBB2 status between primary breast cancer and corresponding distant metastatic sites. Ann. Oncol. 2002; 13; 1036-1043.
18. Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A. Comparison of ERBB2 overexpression in primary breast cancer and metastatic sites and its effect on biologic targeting therapy of metastatic disease. Br. J. Cancer 2005; 93; 552-556.
19. Carlsson J, Nordgren H, Sjostrom J et al. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br. J. Cancer 2004; 90; 2344-2348.
20. Marx AH, Tharun L, Muth J et al. ERBB2 amplification is highly homogenous in gastric cancer. Hum. Pathol. 2009; 40; 769-777.
21. Kim JH, Kim MA, Lee HS, Kim WH. Comparative analysis of protein expressions in primary and metastatic gastric carcinomas. Hum. Pathol. 2009; 40; 314-322.
22. Hoffmann M, Stoss O, Shi D et al. Assessment of a HER2 scoring system for gastric cancer: result from a validation study. Histopathology 2008; 52; 797-805.
23. Cottu PH, Asselah J, Lae M et al. Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer. Ann. Oncol. 2008; 19; 596-597.
24. Kunitomo K, Inoue S, Ichihara F et al. A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel. Hum. Pathol. 2004; 35; 379-381.
25. Wolff AC, Hammon MEH, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007; 25; 118-145.